Delayed diagnosis in X-linked agammaglobulinemia and its relationship to the occurrence of mutations in BTK non-kinase domains

References

• Conley ME. Molecular approaches to analysis of X-linked immunodeficiencies. Annu Rev Immunol. 1992;10:215–238.
   PubMed Web of Science ®Google Scholar
• Conley ME. Genetics of hypogammaglobulinemia: what do we really know? Curr Opin Immunol. 2009;21:466–471.
   PubMed Web of Science ®Google Scholar
• Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–233.
   PubMed Web of Science ®Google Scholar
• Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279–290.
   PubMed Web of Science ®Google Scholar
• Mohamed AJ, Yu L, Backesjo CM, et al. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228:58–73.
   PubMed Web of Science ®Google Scholar
• Yang WC, Collette Y, Nunes JA, et al. Tec kinases: a family with multiple roles in immunity. Immunity. 2000;12:373–382.
   PubMed Web of Science ®Google Scholar
• Stewart DM, Lian L, Nelson DL. The clinical spectrum of Bruton’s agammaglobulinemia. Curr Allergy Asthma Rep. 2001;1:558–565.
   PubMedGoogle Scholar
• Jones A, Bradley L, Alterman L, et al. X linked agammaglobulinaemia with a ‘leaky’ phenotype. Arch Dis Child. 1996;74:548–549.
   PubMed Web of Science ®Google Scholar
• Lim LM, Chang JM, Wang IF, et al. Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient. BMC Pediatrics. 2013;13:150.
   PubMed Web of Science ®Google Scholar
• Lopez-Granados E, Perez de Diego R, Ferreira Cerdan A, et al. A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia. J Allergy Clin Immunol. 2005;116:690–697.
   PubMed Web of Science ®Google Scholar
• Mitsuiki N, Yang X, Bartol SJ, et al. Mutations in Bruton’s tyrosine kinase impair IgA responses. Int J Hematol. 2015;101:305–313.
   PubMed Web of Science ®Google Scholar
• Graziani S, di Matteo G, Benini L, et al. Identification of a BTK mutation in a dysgammaglobulinemic patient with reduced B cells: XLA diagnosis or not? Clin Immunol. 2008;128:322–328.
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Ferrando M, Caragol I, et al. Kinase mutant BTK results in atypical X-linked agammaglobulinaemia phenotype. Clin Exp Immunol. 2000;120:346–350.
   PubMed Web of Science ®Google Scholar
• Mitsui T, Tsukamoto N, Kanegane H, et al. X-linked agammaglobulinemia diagnosed in adulthood: a case report. Int J Hematol. 2006;84:154–157.
   PubMed Web of Science ®Google Scholar
• Basile N, Danielian S, Oleastro M, et al. Clinical and molecular analysis of 49 patients with X-linked agammaglobulinemia from a single center in Argentina. J Clin Immunol. 2009;29:123–129.
   PubMed Web of Science ®Google Scholar
• Lopez-Herrera G, Berron-Ruiz L, Mogica-Martinez D, et al. Characterization of Bruton’s tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia. Mol Immunol. 2008;45:1094–1098.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Tsukada S, Matsushita M, et al. Identification of Bruton’s tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of BTK deficiency in Japan. Blood. 1996;88:561–573.
   PubMed Web of Science ®Google Scholar
• Kanegane H, Futatani T, Wang Y, et al. Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. J Allergy Clin Immunol. 2001;108:1012–1020.
   PubMed Web of Science ®Google Scholar
• Noordzij JG, De Bruin-Versteeg S, Hartwig NG, et al. XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts. J Clin Immunol. 2002;22:306–318.
   PubMed Web of Science ®Google Scholar
• Tani SM, Wang Y, Kanegane H, et al. Identification of mutations of Bruton’s tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammaglobulinemia. Hum Mutat. 2002;20:235–236.
   PubMed Web of Science ®Google Scholar
• Perez De Diego R, Lopez-Granados E, Rivera J, et al. Naturally occurring Bruton’s tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model. Clin Exp Immunol. 2008;152:33–38.
   PubMed Web of Science ®Google Scholar
• Sigmon JR, Kasasbeh E, Krishnaswamy G. X-linked agammaglobulinemia diagnosed late in life: case report and review of the literature. Clin Mol Allergy. 2008;6:5.
   PubMedGoogle Scholar
• Kornfeld SJ, Haire RN, Strong SJ, et al. A novel mutation (Cys145–>stop) in Bruton’s tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Mol Med. 1996;2:619–623.
   PubMed Web of Science ®Google Scholar
• Fujioka T, Kawashima H, Nishimata S, et al. Atypical case of X-linked agammaglobulinemia diagnosed at 45 years of age. Pediat Int: J Japan Pediat Soc. 2011;53:611–612.
   Google Scholar
• Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al. Brief report: a point mutation in the SH2 domain of Bruton’s tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med. 1994;330:1488–1491.
   PubMed Web of Science ®Google Scholar
• Morwood K, Bourne H, Gold M, et al. Phenotypic variability: clinical presentation between the 6th year and the 60th year in a family with X-linked agammaglobulinemia. J Allergy Clin Immunol. 2004;113:783–785.
   PubMed Web of Science ®Google Scholar
• Bulley S, Zhang J, Kwong S, et al. Newly diagnosed X-linked agammaglobulinemia, Bruton’s Tyrosine Kinase (BTK) mutation, in a 39 year-old male. J Aller Clin Immunol. 2002;109:S188.
   Web of Science ®Google Scholar
• Stewart DM, Tian L, Nelson DL. A case of X-linked agammaglobulinemia diagnosed in adulthood. Clin Immunol. 2001;99:94–99.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Miyawaki T, Futatani T, et al. Atypical X-linked agammaglobulinemia diagnosed in three adults. Intern Med. 1999;38:722–725.
   PubMed Web of Science ®Google Scholar
• Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073–1081.
   PubMed Web of Science ®Google Scholar
• Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protocols Human Genet. 2013;Chapter 7:Unit7 20.
   PubMedGoogle Scholar
• Garcia-Garcia E, Staines-Boone AT, Vargas-Hernandez A, et al. Clinical and mutational features of X-linked agammaglobulinemia in Mexico. Clin Immunol. 2016;165:38–44.
   PubMed Web of Science ®Google Scholar
• Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112:973–980.
   PubMed Web of Science ®Google Scholar
• Berron-Ruiz L, Lopez-Herrera G, Avalos-Martinez CE, et al. Variations of B cell subpopulations in peripheral blood of healthy Mexican population according to age: relevance for diagnosis of primary immunodeficiencies. Allergol Immunopathol (Madr). 2016;44:571–579.
   PubMed Web of Science ®Google Scholar
• Velickovic M, Prasad ML, Weston SA, et al. Identification of the bruton tyrosine kinase (BTK) gene mutations in 20 Australian families with X-linked agammaglobulinemia (XLA). Hum Mutat. 2004;23:398–399.
   PubMed Web of Science ®Google Scholar
• De Weers M, Verschuren MC, Kraakman ME, et al. The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol. 1993;23:3109–3114.
   PubMed Web of Science ®Google Scholar
• Lindvall JM, Blomberg KE, Valiaho J, et al. Bruton’s tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev. 2005;203:200–215.
   PubMed Web of Science ®Google Scholar
• Routes J, Abinun M, Al-Herz W, et al. ICON: the early diagnosis of congenital immunodeficiencies. J Clin Immunol. 2014;34:398–424.
   PubMed Web of Science ®Google Scholar
• Chen XF, Wang WF, Zhang YD, et al. Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia: report from Shanghai, China (2000-2015). Medicine. 2016;95:e4544.
   PubMed Web of Science ®Google Scholar
• Behniafard N, Aghamohammadi A, Abolhassani H, et al. Autoimmunity in X-linked agammaglobulinemia: Kawasaki disease and review of the literature. Expert Rev Clin Immunol. 2012;8:155–159.
   PubMed Web of Science ®Google Scholar
• Sharma D, Guleria S, Suri D, et al. A child with X-linked agammaglobulinemia and Kawasaki disease: an unusual association. Rheumatol Int. 2017.
   Web of Science ®Google Scholar
• Ozturk C, Sutcuoglu S, Atabay B, et al. X-linked agammaglobulinemia presenting with secondary hemophagocytic syndrome: a case report. Case Rep Med. 2013;2013:742795.
   PubMedGoogle Scholar
• Cardona F, Tormos-Perez M, Perez-Tur J. Structural and functional in silico analysis of LRRK2 missense substitutions. Mol Biol Rep. 2014;41:2529–2542.
   PubMed Web of Science ®Google Scholar
• Martini H, Enright V, Perro M, et al. Importance of B cell co-stimulation in CD4(+) T cell differentiation: X-linked agammaglobulinaemia, a human model. Clin Exp Immunol. 2011;164:381–387.
   PubMed Web of Science ®Google Scholar
• Sharapova SO, Pashchenko OE, Guryanova IE, et al. Recent thymic emigrants, T regulatory cells, and BAFF level in children with X-linked agammaglobulinaemia in association with chronic respiratory disease. Allergol Immunopathol (Madr). 2017;S0301-0546(17)30051-4.
   PubMedGoogle Scholar
• Bao Y, Zheng J, Han C, et al. Tyrosine kinase BTK is required for NK cell activation. J Biol Chem. 2012;287:23769–23778.
   PubMed Web of Science ®Google Scholar
• Tzeng SR, Pai MT, Lung FD, et al. Stability and peptide binding specificity of BTK SH2 domain: molecular basis for X-linked agammaglobulinemia. Protein Sci: Pub Protein Soc. 2000;9:2377–2385.
   PubMed Web of Science ®Google Scholar
• Yao L, Janmey P, Frigeri LG, et al. Pleckstrin homology domains interact with filamentous actin. J Biol Chem. 1999;274:19752–19761.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Ramars AS, Ochs HD, et al. Bruton’s tyrosine kinase is a substrate of calpain in human platelets. FEBS Lett. 2001;505:37–41.
   PubMed Web of Science ®Google Scholar
• Abbott JK, Ochs HD, Gelfand EW. Coding-region alterations in BTK do not universally cause X-linked agammaglobulinemia. J Allergy Clin Immunol. 2013;132:1246–1248.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Kojima T, Kabayama H, et al. Mutation of the pleckstrin homology domain of Bruton’s tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol Chem. 1996;271:30303–30306.
   PubMed Web of Science ®Google Scholar
• Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–361.
   PubMed Web of Science ®Google Scholar
• Lopez-Herrera G, Vargas-Hernandez A, Gonzalez-Serrano ME, et al. Bruton’s tyrosine kinase–an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol. 2014;95:243–250.
   PubMed Web of Science ®Google Scholar